Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus (OnSeT-2D)
Primary Purpose
Type 2 Diabetes
Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
covivio (additional to treatment as usual)
treatment as usual
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, covivio, diabetes self-management, digital health application
Eligibility Criteria
Inclusion Criteria:
- diagnosis of T2DM (submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90)
- HbA1c value ≥ 7.0% (53 mmol/mol)
- BMI ≥ 23 kg/m2
- Consent to participate
- Sufficient knowledge of the German language
Exclusion Criteria:
- diagnosis of type 1 diabetes mellitus (T1DM)
- change in medication, frequency of use or dosage (planned within 4 weeks before T0 or during the study period)
Sites / Locations
- GAIARecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
online intervention in addition to treatment-as-usual
treatment-as-usual
Arm Description
online intervention: covivio in addition to treatment as usual
Other: treatment as usual
Outcomes
Primary Outcome Measures
HbA1c
The primary objective of this study is to determine whether the online intervention covivio will reduce HbA1c values in the intervention group compared to the control group.
Secondary Outcome Measures
Depressive symptoms
assessed with the total score of the Patient Health Questionnaire (PHQ-9)
Diabetes Self-management
assessed with the total mean score of the Diabetes Self-management questionnaire (DSMQ)
Body Mass Index
calculated from measurement data of patient's height in meter and weight in kilogram
Health-Related Quality of Life
assessed with the total score of the Assessment of Quality of Life (AQoL-8D)
Proportion of patients achieving a reduction in HbA1c
A reduction of HbA1c values by at least 0.3% from baseline to T2 will be considered a significant clinical improvement in glycemic control
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05525117
Brief Title
Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus
Acronym
OnSeT-2D
Official Title
Evaluating the Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus (Covivio): Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 4, 2023 (Actual)
Primary Completion Date
January 15, 2024 (Anticipated)
Study Completion Date
July 15, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gaia AG
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial was designed to evaluate the effectiveness of the dialogue-based online intervention covivio, which was designed to improve diabetes self-management in patients with type 2 diabetes.
The study aims to test the hypothesis that covivio has a greater positive impact on glycemic control than treatment as usual. Patients with type 2 diabetes mellitus will be randomized and allocated to either an intervention group, receiving covivio in addition to treatment as usual, or a control group, which receives only treatment as usual. The primary endpoint is the HbA1c value six month after baseline.
Detailed Description
The aim of this clinical trial is to investigate the effectiveness of the self-guided digital therapeutic covivio in 268 patients with type 2 diabetes mellitus (T2DM). Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 134), or to a control group, in which they will receive only TAU (n = 134).
The primary endpoint of this trial will be the between-groups difference of the HbA1c in the intervention and control group at six months adjusted for the baseline HbA1c. In order to show the course of change over time, two timepoints for assessment of effects are planned at four (T1) and six months (T2) after the baseline assessment (T0). The primary endpoint will be the HbA1c at six months post-allocation. Secondary endpoints will be depression, diabetes self-management (DSM), BMI, and quality of life. Figure 1 (section 6.1) summarizes the design of the clinical trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
type 2 diabetes, covivio, diabetes self-management, digital health application
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) treatment-as-usual
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
268 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
online intervention in addition to treatment-as-usual
Arm Type
Experimental
Arm Description
online intervention: covivio in addition to treatment as usual
Arm Title
treatment-as-usual
Arm Type
Other
Arm Description
Other: treatment as usual
Intervention Type
Behavioral
Intervention Name(s)
covivio (additional to treatment as usual)
Intervention Description
Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
Intervention Type
Other
Intervention Name(s)
treatment as usual
Intervention Description
Participants may continue with any treatment that they require (treatment as usual)
Primary Outcome Measure Information:
Title
HbA1c
Description
The primary objective of this study is to determine whether the online intervention covivio will reduce HbA1c values in the intervention group compared to the control group.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Depressive symptoms
Description
assessed with the total score of the Patient Health Questionnaire (PHQ-9)
Time Frame
6 months
Title
Diabetes Self-management
Description
assessed with the total mean score of the Diabetes Self-management questionnaire (DSMQ)
Time Frame
6 months
Title
Body Mass Index
Description
calculated from measurement data of patient's height in meter and weight in kilogram
Time Frame
6 months
Title
Health-Related Quality of Life
Description
assessed with the total score of the Assessment of Quality of Life (AQoL-8D)
Time Frame
6 months
Title
Proportion of patients achieving a reduction in HbA1c
Description
A reduction of HbA1c values by at least 0.3% from baseline to T2 will be considered a significant clinical improvement in glycemic control
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Waist circumference
Description
measured at the midpoint between the lower rib and iliac crest in centimeters
Time Frame
6 months
Title
systolic blood pressure
Description
measured with a calibrated sphygmomanometer while the subject is sitting
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of T2DM (submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90)
HbA1c value ≥ 7.0% (53 mmol/mol)
BMI ≥ 23 kg/m2
Consent to participate
Sufficient knowledge of the German language
Exclusion Criteria:
diagnosis of type 1 diabetes mellitus (T1DM)
change in medication, frequency of use or dosage (planned within 4 weeks before T0 or during the study period)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gitta Jacob, PD PhD
Phone
+49 40 349930
Ext
374
Email
gitta.jacob@gaia-group.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gitta Jacob, PD PhD
Organizational Affiliation
Gaia AG
Official's Role
Principal Investigator
Facility Information:
Facility Name
GAIA
City
Hamburg
ZIP/Postal Code
22085
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gitta Jacob, PD PhD
12. IPD Sharing Statement
Learn more about this trial
Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs